纺织服饰周专题：Puma2025Q2业绩发布，短期业绩承压，公司下调2025年业绩指引

Investment Rating - The report maintains a "Buy" rating for several key companies in the textile and apparel industry, including Anta Sports, Li Ning, and Xtep International, among others [10][25][26]. Core Insights - Puma's Q2 2025 performance was under pressure, with revenue declining by 2% year-on-year to €1.942 billion, and the company lowered its revenue guidance for 2025 to a low double-digit decline [1][16]. - The overall consumer environment in July showed a volatile recovery, with stable clothing consumption, particularly in the sportswear segment, which is expected to outperform the broader apparel market [3][23]. - The report highlights the strong performance of Direct-to-Consumer (DTC) channels, with DTC revenue growing by 9.2% year-on-year, while wholesale business saw a decline of 6.3% [2][20]. Summary by Sections Puma's Q2 2025 Performance - Puma's revenue on a currency-neutral basis decreased by 2% to €1.942 billion, with a gross margin decline of 0.7 percentage points to 46.1% [1][16]. - The company reported an operating loss of €98 million, with inventory increasing by 9.7% year-on-year to €2.151 billion [1][16]. Regional and Business Model Performance - Sales performance across major regions was weak, with EMEA, Americas, and Asia-Pacific revenues declining by 3.1%, 0.5%, and 2.9% respectively [2][18]. - DTC business showed resilience with a 9.2% increase in revenue, while wholesale business faced a 6.3% decline [2][20]. Market Outlook - The report anticipates a steady trend for comprehensive sports brands, with growth expected to be faster than the overall apparel market [3][23]. - Companies with strong product differentiation and brand power are expected to outperform the industry in 2025 [24][25]. Key Recommendations - The report recommends several companies for investment, including Anta Sports, Xtep International, and Li Ning, highlighting their strong operational capabilities and growth potential [10][25][26]. - It also suggests focusing on companies like Bosideng and Huamao Medical for their attractive valuations and growth prospects [25][26].